[PDF][PDF] Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial
Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …
Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment …
Background There are still many unresolved questions in the management of locally
advanced Head and Neck Cancer (HNC). Many chemotherapeutic drugs and radiotherapy …
advanced Head and Neck Cancer (HNC). Many chemotherapeutic drugs and radiotherapy …
Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments
A Habib - The Journal of Laryngology & Otology, 2018 - cambridge.org
Background: Advanced hypopharyngeal carcinoma has a dismal prognosis. The optimal
treatment for these patients remains under debate. This systematic review aimed to compare …
treatment for these patients remains under debate. This systematic review aimed to compare …
Iridium nanocrystals encapsulated liposomes as near-infrared light controllable nanozymes for enhanced cancer radiotherapy
Owing to the existence of severe tumor hypoxia and limited X-ray absorption of solid tumors,
the therapeutic efficacy of radiotherapy is far from satisfactory. Herein, ultrasmall iridium …
the therapeutic efficacy of radiotherapy is far from satisfactory. Herein, ultrasmall iridium …
Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT era: a multi-institution cohort study by the MIRI collaborative
Purpose The therapeutic ratio of reirradiation for recurrent or second primary (RSP)
squamous carcinoma of the head and neck may be improved in the intensity modulated …
squamous carcinoma of the head and neck may be improved in the intensity modulated …
Oropharyngeal cancer
CH Chapman, SS Yom - Handbook of Evidence-Based Radiation …, 2018 - Springer
Oropharyngeal Cancer | SpringerLink Skip to main content Advertisement SpringerLink
Account Menu Find a journal Publish with us Track your research Search Cart Book cover …
Account Menu Find a journal Publish with us Track your research Search Cart Book cover …
[HTML][HTML] Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
SMF Jamieson, P Tsai, MK Kondratyev, P Budhani… - JCI insight, 2018 - ncbi.nlm.nih.gov
Abstract Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-
crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) …
crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) …
Treatment deintensification in human papillomavirus‐positive oropharynx cancer: outcomes from the National Cancer Data Base
BACKGROUND The growing epidemic of human papillomavirus‐positive (HPV+)
oropharyngeal cancer and the favorable prognosis of this disease etiology have led to a call …
oropharyngeal cancer and the favorable prognosis of this disease etiology have led to a call …
De‐intensified adjuvant (chemo) radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV‐positive …
J Howard, RC Dwivedi, L Masterson… - Cochrane Database …, 2018 - cochranelibrary.com
Background More than 400,000 cases of oropharyngeal squamous cell cancer (OPSCC) are
diagnosed every year worldwide and this is rising. Much of the increase has been attributed …
diagnosed every year worldwide and this is rising. Much of the increase has been attributed …
Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and …
J Faig, M Haughton, RC Taylor… - American journal of …, 2018 - journals.lww.com
Objectives: Cisplatin remains the pivotal chemotherapy in squamous cell carcinoma of the
head and neck (SCCHN), with nephrotoxicity considered the dose-limiting toxicity. The …
head and neck (SCCHN), with nephrotoxicity considered the dose-limiting toxicity. The …